Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report.

World J Gastrointest Oncol · 2023 · PMC10237029 · PMID 37275450

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

Also, the KEYNOTE-240 trial compared the overall survival and progression free survival between pembrolizumab and placebo in advanced HCC patients who were previously treated with sorafenib, and failed to reach statistical significance[ 7 ].

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.